Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AryoGen infliximab versus Remicade in moderate to severe ulcerative colitis
IRCT20150303021315N36Phase 3Recruiting
- Sponsor
- AryoGen Biopharma
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of infliximab in autoimmune colitis (2 arms), sponsored by AryoGen Biopharma. Primary endpoint: Clinical response at week 8. Started May 2025; status: recruiting.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on IRCT20150303021315N36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N36.